Infigratinib: First Approval.

ABSTRACT: Infigratinib (TRUSELTIQ^TM), a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor, is being co-developed by QED Therapeutics and Helsinn for the treatment of cholangiocarcinoma, urothelial carcinoma and other FGFR-driven conditions. Infigratinib was recently approved in the USA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by a test approved by the US Food and Drug Administration. This article summarizes the milestones in the development of infigratinib leading to this first approval for advanced cholangiocarcinoma.

SUBMITTER: Kang C 

PROVIDER: S-EPMC8610935 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature